ES2116528T3 - Nuevo compuesto, la leustroducsina h, su preparacion y su utilizacion terapeutica. - Google Patents

Nuevo compuesto, la leustroducsina h, su preparacion y su utilizacion terapeutica.

Info

Publication number
ES2116528T3
ES2116528T3 ES94302367T ES94302367T ES2116528T3 ES 2116528 T3 ES2116528 T3 ES 2116528T3 ES 94302367 T ES94302367 T ES 94302367T ES 94302367 T ES94302367 T ES 94302367T ES 2116528 T3 ES2116528 T3 ES 2116528T3
Authority
ES
Spain
Prior art keywords
leustroducsine
preparation
new compound
therapeutic use
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94302367T
Other languages
English (en)
Inventor
Yukio Sugimura
Tomoyuki Shibata
Kazuhiko Tamaki
Shinwa Kurihara
Takafumi Kohama
Akio Shiraishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Application granted granted Critical
Publication of ES2116528T3 publication Critical patent/ES2116528T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

UN NUEVO COMPUESTO, EL QUE HEMOS DENOMINADO LEUSTRODUCSIN H, TIENE LA FORMULA (I): Y SALES DEL MISMO FARMACEUTICAMENTE ACEPTABLES. ESTE COMPUESTO PUEDE PREPARARSE MEDIANTE HIDROLISIS DE LEUSTRODUCSINS QUE SE PRESENTAN NATURALMENTE, Y EL COMPUESTO PUEDE USARSE PARA EL TRATAMIENTO DE LA PROFILAXIS DE LA TROMBOCITOPENIA.
ES94302367T 1993-04-23 1994-03-31 Nuevo compuesto, la leustroducsina h, su preparacion y su utilizacion terapeutica. Expired - Lifetime ES2116528T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9805893 1993-04-23

Publications (1)

Publication Number Publication Date
ES2116528T3 true ES2116528T3 (es) 1998-07-16

Family

ID=14209715

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94302367T Expired - Lifetime ES2116528T3 (es) 1993-04-23 1994-03-31 Nuevo compuesto, la leustroducsina h, su preparacion y su utilizacion terapeutica.

Country Status (18)

Country Link
US (1) US5409912A (es)
EP (1) EP0622372B1 (es)
JP (1) JPH072886A (es)
CN (1) CN1050845C (es)
AT (1) ATE166058T1 (es)
AU (1) AU665488B2 (es)
CA (1) CA2121735A1 (es)
CZ (1) CZ286364B6 (es)
DE (1) DE69410159T2 (es)
DK (1) DK0622372T3 (es)
ES (1) ES2116528T3 (es)
FI (1) FI941850L (es)
HU (1) HU220223B (es)
IL (1) IL109227A (es)
NO (1) NO303640B1 (es)
NZ (1) NZ260364A (es)
PH (1) PH30180A (es)
RU (1) RU2098422C1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040335A (en) * 1995-10-17 2000-03-21 Suntory Limited Therapeutics for thrombocytopenia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2865302B2 (ja) * 1988-02-13 1999-03-08 サントリー株式会社 ２―ピラノン誘導体及びその製造法並びにそれを含む抗菌剤
AU649116B2 (en) * 1991-03-27 1994-05-12 Sankyo Company Limited New compounds, named the "Leustroducins", their preparation and their therapeutic uses
JPH05213758A (ja) * 1992-02-06 1993-08-24 Sankyo Co Ltd 血小板増多剤

Also Published As

Publication number Publication date
FI941850A7 (fi) 1994-10-24
DK0622372T3 (da) 1999-02-15
DE69410159T2 (de) 1999-01-28
PH30180A (en) 1997-01-21
EP0622372B1 (en) 1998-05-13
US5409912A (en) 1995-04-25
AU5932394A (en) 1994-10-27
JPH072886A (ja) 1995-01-06
CZ96494A3 (en) 1994-11-16
CN1050845C (zh) 2000-03-29
ATE166058T1 (de) 1998-05-15
HK1007857A1 (en) 1999-04-23
HUT68015A (en) 1995-05-29
IL109227A (en) 1998-01-04
NO303640B1 (no) 1998-08-10
FI941850A0 (fi) 1994-04-21
IL109227A0 (en) 1994-07-31
CN1105027A (zh) 1995-07-12
NO941478D0 (no) 1994-04-22
RU2098422C1 (ru) 1997-12-10
AU665488B2 (en) 1996-01-04
HU220223B (hu) 2001-11-28
FI941850L (fi) 1994-10-24
HU9401159D0 (en) 1994-07-28
DE69410159D1 (de) 1998-06-18
NO941478L (no) 1994-10-24
NZ260364A (en) 1995-07-26
CZ286364B6 (cs) 2000-03-15
CA2121735A1 (en) 1994-10-24
EP0622372A1 (en) 1994-11-02

Similar Documents

Publication Publication Date Title
BR0109703A (pt) Derivados de piperazina
AR121226A1 (es) Compuestos y usos de estos
ES2061252T3 (es) Agente antitusivo y regulador de la mucosa, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
PA8486001A1 (es) Composiciones de celecoxib
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
DK0674642T3 (da) Pyrazolopyrimidiner som CRF-antagonister
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
ES2175127T3 (es) Derivados de la quinazolina y su uso.
ES2163407T3 (es) Derivados piperidinilos tiaciclicos.
AR019496A1 (es) Azalidas de 13 miembros, composiciones farmaceuticas, uso en la preparacion de medicamentos y preparacion de los mismos
ES2157252T3 (es) Aplicacion del riluzol en el tratamiento del neuro-sida.
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
ES2167931T3 (es) Derivados bifenilicos sustituidos por un radical aromatico o heteroaromatico y composiciones farmaceuticas y cosmeticas que los contienen.
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
PL360492A1 (en) Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates
ES2078507T3 (es) Medicinas y derivados de sulfonanilida.
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
ES2190471T3 (es) Procedimiento para producir derivados de guanidina, intermedios de dichos compuestos y su produccion.
CO4130200A1 (es) Inhibidores de proteasa del hiv utiles en el tratamiento del sida
ES2134313T3 (es) Utilizacion de derivados de pregnano para el tratamiento de tumores.
EA200100930A1 (ru) Способ лечения хозл
BR9611276A (pt) Composto formulação farmacêutica processo para tratamento ou profilaxia de doenças ou condições de seres humanos e uso de um composto
ES2086442T3 (es) Derivados de fluoroetilcamptotecina.
ES2116528T3 (es) Nuevo compuesto, la leustroducsina h, su preparacion y su utilizacion terapeutica.
UY27372A1 (es) Derivados de bencimidazol 1-aril-2-n, s u o-sustituidos, su uso para la obtención de medicamentos y preparados farmacéuticos que contienen estos derivados

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 622372

Country of ref document: ES